Opinion|Videos|April 7, 2025
Post-Imatinib Progression: Decision Factors and Treatment Options
Experts discuss key factors influencing decision-making when patients with advanced gastrointestinal stromal tumors (GIST) progress on imatinib, reviewing standard second-line options, considerations for increasing imatinib dosing vs switching to a different tyrosine kinase inhibitor (TKI), and clinical or radiographic patterns that guide therapy changes or dose escalation at progression.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- With imatinib as our established first-line therapy for advanced GIST, what key factors influence your decision-making when patients progress? What are our standard second-line options, and what factors influence this treatment selection?
- What specific clinical or molecular factors would lead you to consider increasing imatinib dosing rather than switching to a different TKI?
- What specific clinical or radiographic patterns at the time of progression signal would definitively guide you to switch therapies vs dose escalation?
Advertisement
Related to this article
Seventy percent of patients with B-cell ALL had residual levels of cancer cells eliminated during treatment with inotuzumab ozogamicin.
In a phase 3 trial analysis, DCVax-L extended OS compared with individual patient data from external control populations in patients with glioblastoma.
Phase 3 ELEVATE data show that adjuvant ensartinib significantly improved disease-free survival vs placebo in resected ALK-positive NSCLC.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
The addition of olaparib to radium‐223 did not significantly impact PROs compared with radium‐223 alone in mCRPC with bone metastases.
Matthew S. Davids, MD, MMSc, discusses data from BRUIN CLL-322 and how they may shake up the CLL treatment paradigm.
In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.
The success of RASolute 302 positions daraxonrasib to transform RAS-mutant pancreatic cancer care and accelerate pan-RAS development across tumors.
Advertisement
Advertisement
Trending on OncLive
1
Cracking the KRAS Code: How Daraxonrasib Is Reshaping Pancreatic Cancer and Beyond
2
INCB123667 Advances to Phase 3 Following Encouraging Activity in Platinum-Resistant Ovarian Cancer
3
FDA Accepts NDA for Varegacestat in Desmoid Tumors
4
ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases
5